<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>PROFORMA INVOICE</title></head><body><div><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">the BioIndustry Association</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (BIA) (RaD0011)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">About </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">the BIA</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Established in 1989, the BIA exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterpri</span><span style="font-family:'Times New Roman'; font-size:11pt">ses trade. The BIA represents innovative healthcare-focused bioscience companies, including over ninety per cent of biotech medicines currently in clinical development in the UK. BIA members are at the forefront of innovative scientific developments target</span><span style="font-family:'Times New Roman'; font-size:11pt">ing areas of unmet medical need and this innovation will lead to </span><span style="font-family:'Times New Roman'; font-size:11pt">better outcomes for patients,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the development of the knowledge economy, and economic growth. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Summary</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The BIA welcomes the opportunity to submit comments </span><span style="font-family:'Times New Roman'; font-size:11pt">to the </span><span style="font-family:'Times New Roman'; font-size:11pt">House of Commons S</span><span style="font-family:'Times New Roman'; font-size:11pt">cience and Technology Select </span><span style="font-family:'Times New Roman'; font-size:11pt">Committee</span><span style="font-family:'Times New Roman'; font-size:11pt">’s call for suggestions </span><span style="font-family:'Times New Roman'; font-size:11pt">for future inquiries on UK R</span><span style="font-family:'Times New Roman'; font-size:11pt">esearch and Development (R</span><span style="font-family:'Times New Roman'; font-size:11pt">&amp;D</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> funding</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Government support for medical </span><span style="font-family:'Times New Roman'; font-size:11pt">R&amp;D</span><span style="font-family:'Times New Roman'; font-size:11pt"> is </span><span style="font-family:'Times New Roman'; font-size:11pt">vitally </span><span style="font-family:'Times New Roman'; font-size:11pt">important in leveraging additional private finance, which should be considered a</span><span style="font-family:'Times New Roman'; font-size:11pt">gainst a back-drop of increased collaborations and partnerships across the sector. Support for the translation of such research must remain a priority to ensure economic impact is maximised. </span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The BIA</span><span style="font-family:'Times New Roman'; font-size:11pt"> suggests that the Committee may wish to look further in</span><span style="font-family:'Times New Roman'; font-size:11pt">to one or more of the following topics which all relate to the funding and financing of R&amp;D in the UK:</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Biomedical Catalyst, crowdfunding, and the UK public markets.</span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The Biomedical Catalyst</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Biomedical Catalyst </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> a highly successful and impactful policy that effectively links academia and industry together, supports collaboration and translation, accelerates medical research and leverages significant private funding. </span><span style="font-family:'Times New Roman'; font-size:11pt">The Biomedical Catalyst is jointly managed by t</span><span style="font-family:'Times New Roman'; font-size:11pt">he Technology Strategy Board and Medical Research Council</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> effectively linking up government organisations to support translational activities. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The fund has been well received by the sector</span><span style="font-family:'Times New Roman'; font-size:11pt"> with the application process relatively straight forward for com</span><span style="font-family:'Times New Roman'; font-size:11pt">panies to adhere to.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Of particular note the Biomedical Catalyst has leveraged significant private capital</span><span style="font-family:'Times New Roman'; font-size:11pt">. In three rounds of funding </span><span style="font-family:'Times New Roman'; font-size:11pt">£81 million </span><span style="font-family:'Times New Roman'; font-size:11pt">has been invested into </span><span style="font-family:'Times New Roman'; font-size:11pt">112</span><span style="font-family:'Times New Roman'; font-size:11pt"> business-led projec</span><span style="font-family:'Times New Roman'; font-size:11pt">ts. This funding has leveraged £68 million</span><span style="font-family:'Times New Roman'; font-size:11pt"> of private capital specifically for those projects. Additionally, successful companies have often been able to leverage additional private capital beyond simply match-f</span><span style="font-family:'Times New Roman'; font-size:11pt">u</span><span style="font-family:'Times New Roman'; font-size:11pt">nding the project costs in part due to the Biomedical Catalyst. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Investors perceive t</span><span style="font-family:'Times New Roman'; font-size:11pt">he Biomedical Catalyst as an important part of the UK funding mix and a stamp of approval as to the quality of medical R&amp;D taking place in the UK.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The BIA believes the Biomedical Catalyst provides a blueprint for government support for other sectors as </span><span style="font-family:'Times New Roman'; font-size:11pt">it leverages significant private capital, accelerates R&amp;D and effectively joins together different public bodies. </span><span style="font-family:'Times New Roman'; font-size:11pt">The Committee could assess whether similar schemes could </span><span style="font-family:'Times New Roman'; font-size:11pt">be applied across other sectors.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For further information please read the BIA’s Biome</span><span style="font-family:'Times New Roman'; font-size:11pt">dical Catalyst report (</span><a href="http://bit.ly/BIA_bmc"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://bit.ly/BIA_bmc</span></a><span style="font-family:'Times New Roman'; font-size:11pt">) or see our infographic (</span><a href="http://bia.me/BIABMCinfographic"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://bia.me/BIABMCinfographic</span></a><span style="font-family:'Times New Roman'; font-size:11pt">).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Crowdfunding</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Crowdfunding takes many forms and is emerging as an</span><span style="font-family:'Times New Roman'; font-size:11pt"> interesting new </span><span style="font-family:'Times New Roman'; font-size:11pt">component of the funding landscape. Forms of equity crowdfunding in particular are relevant to this inquiry given the nature of financing required by many innovative and high-growth companies. With the crowdfunding sector growing and subje</span><span style="font-family:'Times New Roman'; font-size:11pt">ct to regulation</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Committee may consider investigating how the government can effectivel</span><span style="font-family:'Times New Roman'; font-size:11pt">y</span><span style="font-family:'Times New Roman'; font-size:11pt"> harness this funding potential to support R&amp;D and innovation in the UK. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In particular</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> other countries have shown how the concept of c</span><span style="font-family:'Times New Roman'; font-size:11pt">rowdfunding, e.g. large nu</span><span style="font-family:'Times New Roman'; font-size:11pt">mbers </span><span style="font-family:'Times New Roman'; font-size:11pt">of individuals support</span><span style="font-family:'Times New Roman'; font-size:11pt">ing</span><span style="font-family:'Times New Roman'; font-size:11pt"> projects and / or companies, can be nurtured and supported through effective incentivisations and policies. For example, the BIA has proposed that th</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt"> government should introduce Citizens’ Innovation Funds (CIFs)</span><span style="font-family:'Times New Roman'; font-size:11pt">, a form of </span><span style="font-family:'Times New Roman'; font-size:11pt">regulated crowdfunding</span><span style="font-family:'Times New Roman'; font-size:11pt"> that is based </span><span style="font-family:'Times New Roman'; font-size:11pt">on the French Fonds Comunes de Placements dans l’Innovation (FCPI) scheme.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">FCPI is an incentive to encourage investment in innovation by mid-net worth individuals under which funds can be set up by intermediaries to co</span><span style="font-family:'Times New Roman'; font-size:11pt">llect capital and used to finance start-ups and innovative business ventures.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The FCPI scheme is notable for the large sums raised from high numbers of private individuals who are keen to invest in the knowledge economy in a tax efficient form without risking large amounts of their savings. In this way the government is an enabler, </span><span style="font-family:'Times New Roman'; font-size:11pt">rather than a provider, of much needed investment. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The FCPI has been successful in </span><span style="font-family:'Times New Roman'; font-size:11pt">raising almost €</span><span style="font-family:'Times New Roman'; font-size:11pt">6bn and creating over 300 funds run by nearly 40 asset management companies. These funds have invested in over 1,000 companies including in the UK. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The BIA advocates framing the CIF along the same lines. The CIF would be a tax free retail investment product allowing £15,000 per person per annum to be invested in funds which are targeted towards innovative SMEs. The BIA proposes that 60% of assets are </span><span style="font-family:'Times New Roman'; font-size:11pt">invested in private companies that qualify for the SME R&amp;D Tax Credit scheme. The remaining 40% could then be invested freely. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The scheme could also be set up so that research charities are encouraged to offer this type of vehicle to donors, using their </span><span style="font-family:'Times New Roman'; font-size:11pt">investment arms, adding to the sense of venture philanthropy which is prevalent in other jurisdictions such as the United States. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For </span><span style="font-family:'Times New Roman'; font-size:11pt">further information please read the BIA’s report on CIFs (</span><a href="http://bit.ly/biacifreport2"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://bit.ly/biacifr</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">eport2</span></a><span style="font-family:'Times New Roman'; font-size:11pt">).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The UK public markets</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In order for innovative high-growth companies to </span><span style="font-family:'Times New Roman'; font-size:11pt">thrive</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the UK there must be adequate access to the public markets for additional and larger amounts of capital to be secured</span><span style="font-family:'Times New Roman'; font-size:11pt">, in order</span><span style="font-family:'Times New Roman'; font-size:11pt"> to fund further R&amp;D and growth. T</span><span style="font-family:'Times New Roman'; font-size:11pt">his is particularly important in the bioscience sector where the majority</span><span style="font-family:'Times New Roman'; font-size:11pt"> of companies are equity-</span><span style="font-family:'Times New Roman'; font-size:11pt">backed and the development timelines of a product are long and expensive. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Government support for early stage funding, such as the provision of grants throug</span><span style="font-family:'Times New Roman'; font-size:11pt">h the Biomedical Catalyst and other schemes and the creation of a su</span><span style="font-family:'Times New Roman'; font-size:11pt">pportive tax environment for pri</span><span style="font-family:'Times New Roman'; font-size:11pt">vate investment, are important to the translation of medical R&amp;D. However, for those companies to grow further without resorting to being acquired or licens</span><span style="font-family:'Times New Roman'; font-size:11pt">ing their advanced assets for further development by another organisation, larger amounts of capital are required, tha</span><span style="font-family:'Times New Roman'; font-size:11pt">t</span><span style="font-family:'Times New Roman'; font-size:11pt"> the public markets can provide. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Without I</span><span style="font-family:'Times New Roman'; font-size:11pt">nitial Public Offerings</span><span style="font-family:'Times New Roman'; font-size:11pt"> (IPOs)</span><span style="font-family:'Times New Roman'; font-size:11pt"> being a viable route for companies to pursue </span><span style="font-family:'Times New Roman'; font-size:11pt">(</span><span style="font-family:'Times New Roman'; font-size:11pt">should they wish</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> growing a bioscience company to profitability </span><span style="font-family:'Times New Roman'; font-size:11pt">is</span><span style="font-family:'Times New Roman'; font-size:11pt"> difficult.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">In the U</span><span style="font-family:'Times New Roman'; font-size:11pt">K</span><span style="font-family:'Times New Roman'; font-size:11pt"> there has not been a drug-</span><span style="font-family:'Times New Roman'; font-size:11pt">developing bioscience company able to achieve an IPO for a number of years, and by some accounts not since 2007. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">This has reduced the development options o</span><span style="font-family:'Times New Roman'; font-size:11pt">f UK bioscience companies</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> leading to the </span><span style="font-family:'Times New Roman'; font-size:11pt">necessary </span><span style="font-family:'Times New Roman'; font-size:11pt">acquisition of many. When th</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt"> ‘funding ladder’ is not operating effectively throughout</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> it can </span><span style="font-family:'Times New Roman'; font-size:11pt">negatively</span><span style="font-family:'Times New Roman'; font-size:11pt"> impact the </span><span style="font-family:'Times New Roman'; font-size:11pt">appetite</span><span style="font-family:'Times New Roman'; font-size:11pt"> of investors earlier in the development chain.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The Committee could assess the</span><span style="font-family:'Times New Roman'; font-size:11pt"> state of UK public</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">market accessibility for innovative sectors such as the bioscience sector. For example, the UK position can be contrasted to the current position in the US where the public biotech market is highly active, with biotech companies having </span><span style="font-family:'Times New Roman'; font-size:11pt">raised over $8 billion through public offerings in 2013 so far (as at 22 August 2013; source – BioWorld Insight).</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="color:#333333; font-family:'Times New Roman'; font-size:11pt; font-style:italic">August 2013</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:5pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:5pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:5pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:Arial; font-size:5pt">              </span></p></div></body></html>